Who is sponsoring NCT05809921?

NCT05809921 is sponsored by Centre Hospitalier Sud Francilien.

What drugs are being tested in NCT05809921?

Interventions in NCT05809921: alteplase, Alteplase + possible complementary IVT with tenecteplase.

What condition does NCT05809921 study?

NCT05809921 studies Acute Ischemic Stroke Due to Medium-vessel-occlusion.

Is NCT05809921 still recruiting?

NCT05809921 is currently completed. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT05809921: DIVArétro

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dual IntraVenous Thrombolysis Approach (DIVA) in Patients With Medium-vessel-occlusion Strokes: a Retrospective Study

Completed Last updated 7 November 2023

What this trial tests

trial testing alteplase in Acute Ischemic Stroke Due to Medium-vessel-occlusion in 294 participants. Completed in 13 September 2023.

Timeline

17 May 2023

Primary endpoint
13 September 2023

13 September 2023

Quick facts

Lead sponsor	Centre Hospitalier Sud Francilien
Status	Completed
Study type	OBSERVATIONAL
Enrollment	294
Start date	17 May 2023
Primary completion	13 September 2023
Estimated completion	13 September 2023
Sites	1 location across France

Drugs / interventions tested

alteplase (ALTEPLASE) — full drug profile →
Alteplase + possible complementary IVT with tenecteplase — full drug profile →

Conditions studied

Acute Ischemic Stroke Due to Medium-vessel-occlusion — all drugs for Acute Ischemic Stroke Due to Medium-vessel-occlusion →

Sponsor

Centre Hospitalier Sud Francilien

Who can join

18 and older, any sex, with Acute Ischemic Stroke Due to Medium-vessel-occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study (Dual IV thrombolysis Approach (DIVA) study) is to assess a new medical strategy for Medium-vessel-occlusion (MeVO) strokes, based on a second IV thrombolysis with tenecteplase (TNK) for persistent intracranial occlusion on MRI 1-2 hours after standard alteplase infusion. The DIVA-study results were compared with a similar cohort of MeVO strokes patients treated with standard therapy (single IVT with alteplase) during the same timeframe in another stroke unit.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Second-dose intravenous thrombolysis with tenecteplase in alteplase-resistant medium-vessel-occlusion strokes: A retrospective and comparative study.
Chausson N, Olindo S, Laborne FX, Aghasaryan M, et al · · 2024 · cited 2× · PMID 38829011 · DOI 10.1177/23969873241254936

Verify or expand the search:

Other trials of alteplase

Trials testing the same drug.

NCT04915729 — A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physica · Phase 3 · completed
NCT02930837 — Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thro · Phase 3 · completed

Other Centre Hospitalier Sud Francilien trials

Trials by the same sponsor.

NCT07495709 — Reactions to Oro-facial Solicitations : a Predictor of Eating Difficulties for Premature Babies of 36 Weeks Gestation Ad · not yet recruiting
NCT07430293 — Hybrid Closed-Loop Insulin Delivery After Pancreatectomy · NA · not yet recruiting
NCT07414186 — Study of Pre Hospital Management of Polytrauma Patients by Medical Teams From a Department in the Parisian Region · not yet recruiting
NCT07144059 — Impact of Non-medicalized ECG Practices Initiated by SAMU in Dispatch Strategies · not yet recruiting
NCT07329192 — Study on How Parents' Anticipated Choice of a Doctor at the Maternity Hospital Influences the Newborn's First Post-disch · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05809921 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Sud Francilien
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing